Center for Computational Toxicology and Exposure, Office of Research and Development, U.S. EPA, Research Triangle Park, NC, 27711, USA.
Cell Biology, Biosciences Division, Thermo Fisher Scientific, Frederick, MD, 21703, USA.
NPJ Syst Biol Appl. 2021 Jan 27;7(1):7. doi: 10.1038/s41540-020-00166-2.
The ToxCast in vitro screening program has provided concentration-response bioactivity data across more than a thousand assay endpoints for thousands of chemicals found in our environment and commerce. However, most ToxCast screening assays have evaluated individual biological targets in cancer cell lines lacking integrated physiological functionality (such as receptor signaling, metabolism). We evaluated differentiated HepaRG cells, a human liver-derived cell model understood to effectively model physiologically relevant hepatic signaling. Expression of 93 gene transcripts was measured by quantitative polymerase chain reaction using Fluidigm 96.96 dynamic arrays in response to 1060 chemicals tested in eight-point concentration-response. A Bayesian framework quantitatively modeled chemical-induced changes in gene expression via six transcription factors including: aryl hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, farnesoid X receptor, androgen receptor, and peroxisome proliferator-activated receptor alpha. For these chemicals the network model translates transcriptomic data into Bayesian inferences about molecular targets known to activate toxicological adverse outcome pathways. These data also provide new insights into the molecular signaling network of HepaRG cell cultures.
ToxCast 体外筛选计划提供了超过一千种环境和商业中发现的化学物质的浓度反应生物活性数据,这些数据来自于数千种 assay 终点。然而,大多数 ToxCast 筛选试验评估了缺乏整合生理功能(如受体信号转导、代谢)的癌细胞系中的单个生物靶标。我们评估了分化的 HepaRG 细胞,这是一种人肝来源的细胞模型,被认为能够有效地模拟与生理相关的肝信号。通过使用 Fluidigm 96.96 动态阵列,定量聚合酶链反应测量了 93 个基因转录本的表达,以响应在 8 个浓度反应点测试的 1060 种化学物质。贝叶斯框架通过 6 个转录因子(包括芳香烃受体、组成型雄烷受体、孕烷 X 受体、法尼醇 X 受体、雄激素受体和过氧化物酶体增殖物激活受体α)定量模拟了化学物质诱导的基因表达变化。对于这些化学物质,网络模型将转录组数据转化为关于已知激活毒理学不良结局途径的分子靶标的贝叶斯推断。这些数据还为 HepaRG 细胞培养物的分子信号网络提供了新的见解。